Suppr超能文献

依格列净通过抑制成纤维细胞中的 TGF-β/Smad 信号通路减轻博来霉素诱导的肺纤维化。

Evogliptin attenuates bleomycin-induced lung fibrosis via inhibiting TGF-β/Smad signaling in fibroblast.

机构信息

Department of Pharmacy, Dongying People's Hospital, Dongying, China.

出版信息

Eur Rev Med Pharmacol Sci. 2020 Oct;24(20):10790-10798. doi: 10.26355/eurrev_202010_23439.

Abstract

OBJECTIVE

Idiopathic pulmonary fibrosis (IPF) is a pulmonary interstitial fibrosis disease. Excessive activation of fibroblasts in the lung contributes to severe alveoli dysfunction and histological destruction. Evogliptin, a dipeptidyl peptidase IV inhibitor, has been widely used to reduce glucose level in type 2 diabetes, whereas evogliptin treatment to fibrosis process of lung IPF is elusive. The study aimed to investigate the mechanism of evogliptin in transforming growth factor-beta (TGF-β)-activated lung fibroblasts and evaluate the efficacy of evogliptin in lung fibrosis model.

MATERIALS AND METHODS

In lung fibroblast culture, the RNA expression of α-SMA in lung fibroblasts was detected, and α-SMA/COL-1 immunofluorescence co-staining after TGF-β stimulation and evogliptin administration was displayed. Mechanically, the phosphorylation level of Smad2/3 protein in cells was analyzed using Western blotting, and the scratch assay was used to reflect fibroblast proliferation. Furthermore, bleomycin was employed to induce lung fibrosis in mice, and IHC staining and hematoxylin and eosin (HE) & Masson staining were carried out to examine the extracellular matrix (ECM) expression and tissue fibrosis.

RESULTS

The results demonstrated that evogliptin treatment attenuated the activation of fibroblasts and collagen deposition following TGF-β stimulation. Furthermore, the extracellular matrix expression was descended via evogliptin restraining the TGF-β/Smad pathway. Besides, it was also found that evogliptin affected the proliferation degree of lung fibroblasts. In vivo, the COL-1 and α-SMA were significantly reduced through evogliptin treatment compared with the bleomycin group, and fibroblasts and collagenous fiber were remarkably decreased.

CONCLUSIONS

Evogliptin exerts an anti-fibrosis effect on TGF-β induced lung fibroblast activation, which restrains ECM formation and decreases cell proliferation level in fibroblasts. Moreover, the fibroblast infiltration and collagen deposition were ameliorated following evogliptin administration. Therefore, evogliptin serves as a potential implication to protect lung fibrosis.

摘要

目的

特发性肺纤维化(IPF)是一种肺间质纤维化疾病。肺成纤维细胞的过度激活导致严重的肺泡功能障碍和组织学破坏。埃格列净是一种二肽基肽酶-4 抑制剂,已广泛用于降低 2 型糖尿病患者的血糖水平,而埃格列净对肺 IPF 纤维化过程的治疗作用尚不清楚。本研究旨在探讨埃格列净在转化生长因子-β(TGF-β)激活的肺成纤维细胞中的作用机制,并评估埃格列净在肺纤维化模型中的疗效。

材料和方法

在肺成纤维细胞培养中,检测肺成纤维细胞中α-SMA 的 RNA 表达,并用 TGF-β刺激和埃格列净给药后的α-SMA/COL-1 免疫荧光共染色显示。在细胞中,用 Western 印迹分析 Smad2/3 蛋白的磷酸化水平,并用划痕试验反映成纤维细胞的增殖。此外,采用博来霉素诱导小鼠肺纤维化,并用免疫组织化学染色和苏木精和伊红(HE)&马松染色检测细胞外基质(ECM)表达和组织纤维化。

结果

结果表明,埃格列净治疗可减轻 TGF-β刺激后成纤维细胞的激活和胶原沉积。此外,通过埃格列净抑制 TGF-β/Smad 通路,细胞外基质表达下降。此外,还发现埃格列净影响肺成纤维细胞的增殖程度。在体内,与博来霉素组相比,埃格列净治疗可显著降低 COL-1 和α-SMA 的表达,且成纤维细胞和胶原纤维显著减少。

结论

埃格列净对 TGF-β诱导的肺成纤维细胞激活具有抗纤维化作用,可抑制 ECM 的形成并降低成纤维细胞的增殖水平。此外,埃格列净给药后可改善成纤维细胞浸润和胶原沉积。因此,埃格列净可能成为一种保护肺纤维化的潜在药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验